



Contacts: Susan Lehman  
Rockpoint Public Relations  
+1 (510) 832-6006  
[susan@rockpointpr.com](mailto:susan@rockpointpr.com)

Stephanie Tomei  
Public Relations Manager  
+1 (408) 789-4234  
[stomei@accuray.com](mailto:stomei@accuray.com)

### **Accuray Wins Innovations in Healthcare<sup>SM</sup> ABBY Award**

*Award from Adaptive Business Leaders (ABL) Organization Recognizes Companies with Transformative Advances in Healthcare*

**SUNNYVALE, Calif., April 30, 2008**– Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the company won the *Innovations in Healthcare<sup>SM</sup>* ABBY Award from the Adaptive Business Leaders (ABL) Organization in the "Innovations in Medical/Diagnostics Technology" category.

Out of 74 total nominations – the largest pool of nominees in the Award's ten-year history – 46 companies were selected as semi-finalists and then further narrowed down to eight finalists in three categories – healthcare delivery, healthcare IT, and medtech. Then CEOs from the eight finalist companies presented to an audience of more than 150 healthcare CEOs and senior executives at the 10<sup>th</sup> Annual Awards event on April 23, 2008 in Costa Mesa, Calif. The audience then voted for an ABBY Award winner in each category.

"Accuray is a quintessential ABBY winner, because they've already proven with their CyberKnife Robotic Radiosurgery System that medical technology can actually *lower* the cost of providing quality healthcare – and at the same time produce a result that saves time for the patient, not to mention providing a "scarless" result," said Mimi Grant, president of the ABL Organization, which hosted the event and is celebrating its 25th anniversary year.

Accuray's presentation at the ABBY Awards event focused on the key benefits of CyberKnife radiosurgery over surgery, including non-invasive delivery, outpatient procedure, minimal-to-no side effects and no down time. The presentation also indicated that in some cases CyberKnife radiosurgery can lower the cost of cancer treatment by as much as 50 percent by avoiding the need for surgery.

For 10 years, ABL's ABBY Awards have recognized organizations that have demonstrated transformative advances in medical devices, diagnostics, therapeutics, information technology and innovative approaches to providing health and coverage, decreasing the numbers of uninsured, and engaging consumers more actively in their healthcare and well-being, all of which reduce the cost of providing healthcare.

Complete event details are available at <http://www.abl.org/iih2008.htm>.

**About the Adaptive Business Leaders (ABL) Organization:**

Celebrating its 25th anniversary year, the Adaptive Business Leaders (ABL) Organization's mission is to help health and technology leaders grow great companies. ABL does this through its monthly, industry-specific Round Tables and frequent Events. In their confidential Round Tables, ABL Members - who are CEOs, Presidents, COOs and Division General Managers - openly seek from and share with each other candid advice, best practices and innovative approaches for capitalizing on market trends and opportunities, in order to assure they are well positioned for business and personal success.

**About the CyberKnife® Robotic Radiosurgery System**

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

**About Accuray**

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 125 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit [www accuray.com](http://www accuray.com).

**Safe Harbor Statement**

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and market acceptance and commercialization of products and services are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance

and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission.. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

###